Thymosin Alpha-1
28-amino acid peptide that primes T-cell maturation and rebalances innate immune response.
Synthetic version of an endogenous thymic peptide. Approved as Zadaxin in 35+ countries for hepatitis B/C and as adjuvant therapy. Modulates TLR9 signaling, expands T-cell repertoires. Recovery use is off-label, framed around immune resilience after intense training or illness.
Not FDA-approved as Zadaxin in the US. Dose for recovery off-label use is heuristic — clinical doses are for hepatitis indications.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- BModerate evidence
Thymosin Alpha-1 — primary mechanism: 28-amino acid peptide that primes t-cell maturation and rebalances innate immune response.
3 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 1.6 mg · twice weekly, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA Cat. 1 — used as Zadaxin elsewhere (35+ countries)